Skip to contentS
Syndax Pharmaceuticals Inc
S
SNDXSyndax Pharmaceuticals Inc Q2 2022 · 10-Q
Revenue—
Net Income-$37.57M-$37.57MN/M vs Q2 2021 EPS Diluted-$0.62-$0.62N/M vs Q2 2021 Operating Income-$37,724,000N/M Operating Cash Flowderived-$40,306,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR
ended Jun 30, 2022 · filed Aug 8, 2022 · 39 d after period end